A randomized phase III study to compare the effects of low-molecular weight heparin and unfractionated heparin in the prevention of proximal deep vein thrombosis in a critically ill population.

Trial Profile

A randomized phase III study to compare the effects of low-molecular weight heparin and unfractionated heparin in the prevention of proximal deep vein thrombosis in a critically ill population.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2014

At a glance

  • Drugs Dalteparin sodium (Primary) ; Heparin
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Therapeutic Use
  • Acronyms PROTECT
  • Most Recent Events

    • 22 Mar 2011 Results published in the New England Journal of Medicine.
    • 07 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Apr 2010 Additional lead trial investigator [Ostermann M] and additional location [England] identified as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top